Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
196
resultados
Última actualización
23/10/2026 [06:53:00]
Resultados 150 a 175 de 196
Resumen de: CN122642897A
The invention discloses a blood glucose evaluation method, a user interface and a related device, and the method can obtain a PPG signal of a user, and then displays a blood glucose result of the user evaluated based on the PPG signal, and the blood glucose result indicates a stage of the user from normal blood glucose to diabetes mellitus. Therefore, the method considers that a development stage still exists before normal blood sugar is converted into diabetes, so that the blood sugar condition of the user is evaluated more finely, and the user can manage the blood sugar more finely.
Resumen de: CN122648357A
The invention discloses a mesenchymal stem cell preparation for expressing FOXO3 and FGF21 and application of the mesenchymal stem cell preparation, and relates to biological medicine, and parental plasmids, carrying therapeutic genes, of mesenchymal stem cells for expressing FOXO3 and FGF21 have a nucleotide sequence as shown in SEQ ID No: 01; the invention provides a mesenchymal stem cell preparation capable of simultaneously expressing FOXO3 and FGF21, the insulin glucose tolerance can be effectively improved, the content of glycosylated hemoglobin is effectively reduced, and the mesenchymal stem cell preparation has the potential of treating human type 2 diabetes mellitus.
Resumen de: CN122643650A
The invention discloses a rehabilitation training device for a diabetic sarcopenia patient. The rehabilitation training device comprises a fixing module, a training module, a blood glucose monitoring module and a controller. The fixing module is detachably mounted at the tail of a sickbed; each training module comprises two guide sliding frames arranged side by side and a pedal sliding block sliding along the guide sliding frames, the angles of the guide sliding frames are adjustable, the guide sliding frames are provided with electromagnetic resistance adjusting mechanisms, and the distance between the two training modules is adjustable; the blood glucose monitoring module comprises an abdominal belt wound on the abdomen of a patient and a blood glucose sensor arranged on the abdominal belt; the controller is connected with the adjusting mechanisms and the blood glucose sensor and automatically adjusts the resistance according to the blood glucose reading. Bedside lower limb rehabilitation training of a bedridden patient is achieved, training safety is guaranteed through blood glucose-resistance intelligent linkage, and the intelligent lower limb rehabilitation training device can meet the requirements of patients of different body types and different rehabilitation stages.
Resumen de: CN224686133U
The utility model discloses a safe disinfection type insulin pen point device, which is characterized in that an independent disinfection device and a disinfection cavity internally provided with an alcohol-containing disinfection cotton piece are additionally arranged at the interface of the traditional insulin pen point, and a circular plastic bulge at the bottom of the cotton piece is matched with an insulin pen groove, so that effective disinfection is realized, clinical disinfection specifications are met, and meanwhile, the insulin pen point device is safe and reliable. The insulin pen point is provided with an anti-stabbing device, the needle point is sealed and wrapped after injection through a one-way telescopic sleeve and a rubber plug, and stabbing is avoided. The use safety of patients and medical staff is guaranteed, the local infection risk of the patients is reduced, and the safety and reliability of insulin treatment are improved.
Resumen de: CN224686128U
The utility model discloses an insulin pump flow detection assembly with a quick plug interface, which comprises a mounting pipe, a liquid flowmeter is mounted in the mounting pipe, first connecting pipes are mounted at two ends of the mounting pipe respectively, second connecting pipes are inserted into the first connecting pipes in a threaded manner, and the second connecting pipes are connected with the quick plug interface. The outer diameter of the runner pipe is larger than that of the first connecting pipe, the inner diameter of the runner pipe is smaller than that of the first connecting pipe, a first sealing ring is arranged at the end, close to the second connecting pipe, of the runner pipe, and the first sealing ring is located in the first connecting pipe. The insulin pump flow detection assembly solves the problems that a traditional insulin pump flow detection assembly mostly adopts a fixed interface or a threaded connection mode, a fixed interface structure is complex in operation during replacement or maintenance, rapid insertion and extraction are difficult to achieve, and the flow detection assembly is inconvenient to use. And under the long-term use or external force action of a threaded connection structure, the connection part is easy to loosen.
Resumen de: NZ799609A
An applicator assembly comprising a body-attachable unit configured to adhere to a user’s skin and an applicator for deploying the unit. The body-attachable unit includes a housing, a sensor module having a sensor probe for subcutaneous insertion and a sensor body disposed within the housing, a printed circuit board (PCB) with electrical contact points, and a press manipulation module operable by a user. The press manipulation module is configured to apply pressure to at least a portion of the sensor body to bring it into electrical contact with the PCB contact points, thereby initiating operation. The applicator is adapted to move the body-attachable unit from a first position within the applicator to a second position where the sensor probe is inserted into the user’s skin. The sensor body unit is spaced apart from the electrical contact point of the PCB board when the body attachable unit is in the first position.
Resumen de: CN122642899A
The invention discloses a non-invasive blood glucose estimation method, system and equipment constructed based on dual-wavelength channel coupling characteristics and a storage medium, and belongs to the technical field of non-invasive physiological detection. The method comprises the following steps: acquiring a dual-wavelength photoelectric volume pulse wave signal, respectively preprocessing a red light channel signal and an infrared light channel signal, extracting corresponding single-channel pulse wave features, constructing candidate coupling features based on the corresponding features, and screening or combining the candidate coupling features to form a target feature set; and inputting the target feature set into a blood glucose estimation model to obtain a blood glucose estimation value or a blood glucose risk index. According to the method, the stability, robustness and generalization ability of noninvasive blood glucose estimation are improved.
Resumen de: CN122648465A
The invention discloses a transformation method of sugarcane protoplast. The transformation method comprises the following steps: preparing a sugarcane protoplast suspension; introducing the recombinant plasmid into the sugarcane protoplast by utilizing PEG (Polyethylene Glycol) mediation; wherein the recombinant plasmid comprises an expression cassette driven by a promoter element, and the promoter element is selected from one of a ZmUbi promoter, a 35S promoter, a CmYLCV promoter, a MAS + CmYLCV composite promoter or a CmYLCV + MAS composite promoter. The method disclosed by the invention can be applied to the construction of a transient expression system of the sugarcane protoplast, the activity evaluation of a promoter, the expression of a target protein, the expression of a reporter gene, the gene function research, the expression of a gene editing element and the like.
Resumen de: CN122642884A
The invention relates to the technical field of diabetic foot risk monitoring, in particular to a diabetic foot risk dynamic monitoring system based on wearable equipment. The system comprises a data acquisition module for acquiring bone key points, pressure and glycosylated hemoglobin detection values of feet of a target person; the dynamic feature extraction module constructs a skeleton proximity vector based on the proximity degree of sensor nodes and skeleton key points; according to the distance between the sensor nodes and the glycosylated hemoglobin detection value, determining the pressure diffusion connectivity between the sensor nodes; optimal transmission cost calculation is carried out on the pressure and ideal safety distribution constructed based on skeleton proximity vectors, and a local accumulation index is obtained in combination with pressure diffusion connectivity; the risk assessment module obtains a cumulative load index according to the pressure in the gait cycle, the distribution form deviation index and the local accumulation index, and then outputs a corresponding risk prompt. The accuracy of the diabetic foot risk dynamic monitoring result is improved.
Resumen de: CN122642840A
The invention relates to the technical field of medical image processing, and discloses a diabetic foot complex wound necrotic tissue recognition method and system based on multispectral polarization imaging and microcirculation blood oxygen atlas, and the method comprises the steps: obtaining wound collection data and inverting percolate optical parameters; performing surface reflection deduction based on the optical parameters of the percolate; extracting a necrotic tissue feature map; and microcirculation blood oxygen correction and necrosis probability segmentation are carried out. In the prior art, necrosis determination is carried out based on a single spectral parameter, and especially under the condition that a diabetic foot wound surface is covered by an exudate with large viscosity and component concentration changes, deep tissue reflection feature extraction cannot be realized. According to the method, through optical parameter inversion of the percolate, Stokes polarization decomposition and dynamic wave band selection, collaborative recognition of spectral characteristics and microcirculation blood oxygen information of the necrotic tissue under percolate interference is achieved, and the accuracy of recognition of the necrotic tissue of the complex wound surface of the diabetic foot is improved.
Resumen de: CN122647585A
The invention discloses a CD19 targeting bifunctional bridging molecule and application thereof in improving the targeting property and curative effect of CAR-T (Chimeric Antigen Receptor-T) cells. Aiming at the bottlenecks of lack of solid tumor targets and antigen heterogeneity, a bifunctional bridging molecule DBCO-CD19 is specifically and covalently anchored on a metabolic marker tumor cell of which the surface expresses an azide group (-N3) by utilizing metabolic sugar engineering and copper-free click chemistry, so that a CD19 antigen is presented on the surface of the tumor cell. According to the strategy, a heterogeneity tumor map is converted into a single standard CD19 target spot, and dependence on natural antigen expression is avoided. By means of the bridging molecule, accurate immune recognition can be established between the CD19 CAR-T cells and target cells, and formation of stable immune synapses is induced. Researches prove that the strategy can drive CAR-T cells to efficiently remove various tumors, deep infiltration of three-dimensional tumor balls is remarkably enhanced, and remarkable and continuous tumor regression is shown.
Resumen de: CN122648344A
The invention designs a method for carrying out in-situ engineering on immune T cells through a chemical means. 4-(hydrazinocarbonyl) phenylboronic acid (PBA-Hz) is selected as an immune cell engineering tool. Galactose oxidase (GAO) is used for oxidizing galactose at the tail end of a sugar chain on the surface of the immune T cell and acetylgalactosamine to generate an aldehyde group, so that the aldehyde group is covalently connected with hydrazide of PBA-Hz, and the engineered cell TPBA is obtained. The phenylboronic acid on the surface of the TPBA cell can be specifically and covalently bound with sialic acid on the tumor cell, so that the TPBA cell can better target the tumor cell for killing. Meanwhile, sialic acid sites on the surfaces of tumor cells are blocked, so that sialic acid binding immunoglobulin-like lectin on the surfaces of natural killer (NK) cells cannot be combined with sialic acid, and immunosuppression on the NK cells is relieved. The invention relates to a novel engineering immune cell therapy, which has application potential in related diseases such as cancer and the like.
Resumen de: US20260249003A1
The disclosed relates to an insulin syringe replacement system for an insulin pump. The system comprises: a control unit for controlling the operation of the insulin pump; an operation unit for performing an initialization setting operation when an insulin syringe is replaced under the control of the control unit; and a battery unit for supplying power to the control unit and the operation unit; a housing unit for mounting the insulin syringe; and a sensor unit for confirming whether a stopper of the insulin syringe mounted on the housing unit is coupled and notifying the control unit of the confirmation, wherein the control unit controls the operation unit to perform the initialization setting operation only after receiving the confirmation from the sensor unit that the stopper of the insulin syringe mounted on the housing unit is coupled.
Resumen de: US20260249007A1
0000 A technique for treating diabetes that recognizes patient insulin sensitivity is a time-varying physiological parameter. The described techniques for treating diabetes include measuring interstitial fluid glucose concentration, reading insulin delivery data, determining patient insulin sensitivity based on the interstitial fluid glucose concentration and insulin delivery data, and a time-varying physiological parameter, and dispensing an insulin dose from an insulin delivery device based on the determined patient insulin sensitivity.
Resumen de: AU2025213042A1
Disclosed herein is a healthcare management system and method utilizing machine learning based predictive analytics to improve patient adherence rates for chronic care management (e.g., diabetes). An example system may include a computing device configured to establish a customer analytical record to synthetize over a plurality of selected attributes to form a patient centric view of patient behaviors, attitude, characteristics based upon data related to chronic disease state management and social determinants of health, consumer experience to determine, using a predictive artificial intelligence model, a patient's predictive adherence for next 1-3 months, and determine tailored intervention plans to engage patients for continuing adherence.
Resumen de: AU2025224752A1
Exemplary embodiments relate to drug delivery devices, such as automated insulin delivery (AMD) devices. The described methods and apparatuses allow an AMD device to be initialized and/or operated with little or no user input. Exemplary logic initializes the AMD device to operate with known-safe drug delivery parameters that leverage the AMD device's ability to monitor blood glucose levels at short intervals and continuously deliver small amounts of insulin. The AMD then rapidly adapts the parameters and system constraints based on current and historical glucose measurements. Further embodiments provide for the detection of events that result in disturbances to glucose control, and to adaptation of alert frequency based on user behavior.
Resumen de: AU2026214068A1
A stool resuspension solution comprising a hemoglobin stabilization reagent is provided. In some embodiments, the hemoglobin stabilization reagent may be an osmolyte, a polyvalent cation, a sugar or polysaccharide and, optionally, a polyvalent cation, a protoporphyrin,or an HRP stabilization component and, optionally, a polyvalent cation. A method of stabilizing hemoglobin in a stool sample in the solution is also provided, as well as a sample collection device containing the solution. ug u g
Resumen de: US20260253702A1
0000 The system according to the embodiment comprises a collection unit, an analysis unit, and a notification unit. The collection unit collects vital data. The analysis unit analyzes data collected by the collection unit and predicts changes in blood glucose levels. The notification unit notifies the timing of insulin injection based on the changes in blood glucose levels predicted by the analysis unit. The notification unit notifies the user and contacts when hypoglycemia is detected.
Resumen de: WO2026175096A1
Provided in the present application are a blood glucose monitoring method and a related apparatus. In the method, the blood glucose level at a first moment can be acquired on the basis of a glucose concentration in interstitial fluid at the first moment, a glucose concentration in the interstitial fluid within a time period before the first moment and a glucose concentration in the interstitial fluid within a time period after the first moment. In the present application, the glucose concentration in the interstitial fluid within the time period after the first moment is taken into consideration, and an additional time period is provided for the diffusion of glucose between the interstitial fluid and blood; therefore, when the blood glucose level drastically changes, the glucose concentration in the interstitial fluid more closely approximates the blood glucose level, and thus the accuracy of blood glucose monitoring can be improved.
Resumen de: WO2026177370A1
A method for adjusting insulin comprises the steps of: an analysis apparatus acquiring carbohydrate intake data, continuous blood glucose data, and insulin administration data; the analysis apparatus determining a meal time point on the basis of the continuous blood glucose data; the analysis apparatus setting, as a pre-meal blood glucose value, a minimum blood glucose value during a preset period before the meal time point; and the analysis apparatus determining, on the basis of the pre-meal blood glucose value, the amount of insulin to be injected.
Resumen de: US20260253354A1
A system and method for interactive three-dimensional visualization of physiological stress effects on the human body uses biomarker correlation algorithms to determine physiological responses to physical trauma and toxic stress events. The system receives stress event data, calculates biomarker levels including cortisol, blood pressure, blood sugar, and inflammatory markers, and identifies affected organ systems including cardiovascular, nervous, endocrine, digestive, immune, and reproductive systems. Three-dimensional anatomical models are modified with visual characteristics depicting stress-induced changes based on the biomarker data, including color alterations, geometric deformations, and animated effects. A temporal progression interface enables visualization of immediate, short-term, and long-term physiological effects. Spatial audio synchronized with visual animations provides immersive auditory feedback. Cross-platform rendering modules optimize visualization for mobile devices, desktop computers, tablets, virtual reality headsets, and augmented reality glasses. The system provides for real-time interactive manipulation of anatomical visualizations, particularly for pediatric toxic stress education related to corporal punishment.
Resumen de: US20260248422A1
A personal electronic device and wearable sensing system includes one or more dermal-contact electrochemical sensors integrated into one or more skin-contact surfaces of the electronic device, wearable, accessory, or interactive electronic system. The electrochemical sensors obtain measurements indicative of one or more analyte classes associated with a user. One or more additional sensors obtain non-electrochemical measurements associated with the user. A sensor-fusion module derives electrochemical and non-electrochemical features and generates a unified state estimate. One or more inference modules determine a user-state output based on the unified state estimate and a comparison of electrochemical-derived information, or features derived therefrom, to an individualized baseline reference profile associated with the user. In some embodiments, the analyte classes include endogenous physiological markers including glucose-related markers, exogenous exposure analytes, or both. In some embodiments, a credential derived from the individualized baseline reference profile is portable across multiple authorized devices within a trusted ecosystem.
Resumen de: US20260248419A1
Provided is a blood glucose data management method including identifying first blood glucose data based on a blood glucose sensor, identifying a verification dataset corresponding to the first blood glucose data, estimating whether at least a portion of the blood glucose sensor is detached from a user's body based on a comparison between a pattern corresponding to the verification dataset and a reference pattern, and suspending output of the first blood glucose data if detachment is estimated.
Resumen de: EP4796143A2
0001 Disclosed are systems, devices, methods and computer-readable medium products that implement a vibrational event by a wearable drug delivery device. The wearable drug delivery device includes vibrational actuators that vibrate in response to a control signal from a controller. The controller may be controlled by an external device that issues command signals with instructions related to settings of the vibrational event. The vibrational event settings may be modified based on signals received from sensors on the wearable drug delivery device. The vibrational events may be implemented as an element of a site maintenance plan that alleviates the degeneration of tissue at one or more body attachment sites of the wearable drug delivery device.
Nº publicación: EP4796034A2 26/08/2026
Solicitante:
I SENS INC [KR]
i-Sens, Inc.
Resumen de: EP4796034A2
0001 The present disclosure relates to a body-attachable unit for continuously measuring blood glucose. As the body-attachable unit is manufactured to be assembled in an applicator, additional effort is minimized such that the body-attachable unit can be attached to the body by simply operating the applicator. In particular, since the body-attachable unit is provided with a wireless communication chip such that communication with an external terminal is possible, the body-attachable unit can be used simply and conveniently without additional work of connecting a separate transmitter, and thus can be maintained more easily. In addition, since the body-attachable unit is operated by an operation of a user after being attached to the body, the start time of the operation can be adjusted to an appropriate time according to the needs of the user. Accordingly, the body-attachable unit can be operated in a stabilized state, thereby allowing for more accurate blood glucose measurement.
BOPI
Sede Electrónica
